Evidence map›Paper›PMID 27040652›Full record

ArticleBiochimica et biophysica acta2016

Effect of the achondroplasia mutation on FGFR3 dimerization and FGFR3 structural response to fgf1 and fgf2: A quantitative FRET study in osmotically derived plasma membrane vesicles.

Sarvenaz Sarabipour, Kalina Hristova

Open access · greenAbstract read
In one paragraph

Article in Biochimica et biophysica acta, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. β2-adrenoceptor ligand efficacy is tuned by a two-stage interaction with the Gαs C terminus.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sarvenaz SarabipourDepartment of Materials Science and Engineering, Johns Hopkins University, Baltimore, MD 21218, United States.
Kalina HristovaDepartment of Materials Science and Engineering, Johns Hopkins University, Baltimore, MD 21218, United States. Electronic address: kh@jhu.edu.
Johns Hopkins University · US

Funding

Seeking the Physical Basis of AchondroplasiaR01GM068619 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI HRISTOVA, KALINA · 2004 to 2022
$5.4M
NIGMS NIH HHS R01 GM068619
6 · The paper itself

Abstract

The G380R mutation in the transmembrane domain of FGFR3 is a germline mutation responsible for most cases of Achondroplasia, a common form of human dwarfism. Here we use quantitative Fӧster Resonance Energy Transfer (FRET) and osmotically derived plasma membrane vesicles to study the effect of the achondroplasia mutation on the early stages of FGFR3 signaling in response to the ligands fgf1 and fgf2. Using a methodology that allows us to capture structural changes on the cytoplasmic side of the membrane in response to ligand binding to the extracellular domain of FGFR3, we observe no measurable effects of the G380R mutation on FGFR3 ligand-bound dimer configurations. Instead, the most notable effect of the achondroplasia mutation is increased propensity for FGFR3 dimerization in the absence of ligand. This work reveals new information about the molecular events that underlie the achondroplasia phenotype, and highlights differences in FGFR3 activation due to different single amino-acid pathogenic mutations.

Indexed as

MutationAchondroplasiaAmino Acid SequenceAmino Acid SubstitutionAnimalsBacterial ProteinsCell MembraneCHO CellsCricetulusExtracellular VesiclesFibroblast Growth Factor 1Fibroblast Growth Factor 2Fluorescence Resonance Energy TransferGene Expression RegulationGenes, ReporterHumansBacterial ProteinsFGFR3 protein, humanFibroblast Growth Factor 1Fibroblast Growth Factor 2LigandsLuminescent ProteinsReceptor, Fibroblast Growth Factor, Type 3Red Fluorescent Proteinyellow fluorescent protein, BacteriaAchondroplasiaDimerizationDimer stabilityFibroblast growth factor receptor 3Receptor tyrosine kinasesskeletal disorders

Identifiers

PMID27040652
PMCPMC4870120
OpenAlexW2314344364

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.